{"organizations": [], "uuid": "0f46a0add233579bc83790c13658b6b114751826", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-blueprint-medicines-q4-loss-per-sh/brief-blueprint-medicines-q4-loss-per-share-1-23-idUSASB0C6ML", "country": "US", "domain_rank": 408, "title": "BRIEF-Blueprint Medicines Q4 Loss Per Share $1.23", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-21T14:13:00.000+02:00", "replies_count": 0, "uuid": "0f46a0add233579bc83790c13658b6b114751826"}, "author": "", "url": "https://www.reuters.com/article/brief-blueprint-medicines-q4-loss-per-sh/brief-blueprint-medicines-q4-loss-per-share-1-23-idUSASB0C6ML", "ord_in_thread": 0, "title": "BRIEF-Blueprint Medicines Q4 Loss Per Share $1.23", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "blueprint medicines corp", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 15 PM / Updated 7 minutes ago BRIEF-Blueprint Medicines Q4 Loss Per Share $1.23 Reuters Staff Feb 21 (Reuters) - Blueprint Medicines Corp: * BLUEPRINT MEDICINES REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS * Q4 LOSS PER SHARE $1.23 * Q4 EARNINGS PER SHARE VIEW $-1.11 -- THOMSON REUTERS I/B/E/S * BLUEPRINT MEDICINES - EXPECTS EXISTING CASH, CASH EQUIVALENTS AND INVESTMENTS TO FUND OPERATING EXPENSES, CAPITAL EXPENDITURES INTO MIDDLE OF 2020 * AS OF DEC 31, 2017, CASH, CASH EQUIVALENTS AND INVESTMENTS OF $673.4 MILLION, VERSUS $268.2 MILLION AS OF DEC 31, 2016 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-21T14:13:00.000+02:00", "crawled": "2018-02-21T14:32:30.000+02:00", "highlightTitle": ""}